

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3855544

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
SEQUENCE:	5

CONVEYING PARTY DATA

Name	Execution Date
NOVARTIS AG	03/20/2015

RECEIVING PARTY DATA

Name:	GLAXOSMITHKLINE BIOLOGICALS SA
Street Address:	RUE DE L'INSTITUT 89
City:	RIXENSART
State/Country:	BELGIUM
Postal Code:	1330

PROPERTY NUMBERS Total: 2

Property Type	Number
Application Number:	15015004
Application Number:	15015041

CORRESPONDENCE DATA

Fax Number: (415)268-7522

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 415-268-6846

Email: mstout@mofo.com

Correspondent Name: OTIS LITTLEFIELD

Address Line 1: MORRISON & FOERSTER LLP

Address Line 2: 425 MARKET STREET

Address Line 4: SAN FRANCISCO, CALIFORNIA 94105-2482

ATTORNEY DOCKET NUMBER:	303822001206 303822001207
NAME OF SUBMITTER:	OTIS LITTLEFIELD
SIGNATURE:	/Otis Littlefield/
DATE SIGNED:	05/02/2016

Total Attachments: 2

source=5_30382-20012_Novartis_AG_to_GSK#page1.tif

source=5_30382-20012_Novartis_AG_to_GSK#page2.tif

CONFIRMATORY ASSIGNMENT

WE NOVARTIS VACCINES AND DIAGNOSTICS SRL a company limited by shares duly incorporated in Italy whose registered office is at Via Fiorentina 1, I-53100 Siena, Italy do hereby declare that we are the sole owner of the following US patents

US 7,862,827 issued January 4, 2011, entitled "Combination Neisserial Compositions"


US 8,663,656 issued March 4, 2014 entitled "Polypeptide Vaccines For Broad Protection Against Hypervirulent Meningococcal Lineages"

Whereas in accordance with the Patent Assignment Agreement dated 26 February 2015 between NOVARTIS VACCINES AND DIAGNOSTICS SRL and NOVARTIS AG, for good and valuable consideration, the receipt of which is hereby acknowledged, we NOVARTIS VACCINES AND DIAGNOSTICS SRL have assigned the entire right, title and interest and from which priority may be claimed from one or more applications, or any division, continuation and continuation-in-part of said application to in and to said patent application and all countries in which this/ these application(s) are filed to NOVARTIS AG of Lichtstrasse 35, 4056 Basel, Switzerland


And in accordance with the Intellectual Property Assignment Agreement dated 2 March 2015 between NOVARTIS AG and GLAXOSMITHKLINE BIOLOGICALS SA, for good and valuable consideration, the receipt of which is hereby acknowledged, we NOVARTIS AG have assigned the entire right, title and interest and from which priority may be claimed from one or more applications, or any division, continuation and continuation-in-part of said application to in and to said patent application and all countries in which this/ these application(s) are filed to GLAXOSMITHKLINE BIOLOGICALS SA of Rue de l'Institut 89, 1330 Rixensart, Belgium.

Dated this 20th day of March 2015.

Signed for and on behalf of
NOVARTIS AG and NOVARTIS VACCINES AND DIAGNOSTICS SRL.




Marco Riensche
Authorized Signatory on behalf of
NOVARTIS AG and NOVARTIS VACCINES AND DIAGNOSTICS SRL.



Kathleen Bastarache
Authorized Signatory on behalf of
NOVARTIS AG and NOVARTIS VACCINES AND DIAGNOSTICS SRL.

1/2

Signed for and on behalf of
GLAXOSMITHKLINE BIOLOGICALS SA



Rachel M Thornley
Authorized Official on behalf of
GLAXOSMITHKLINE BIOLOGICALS SA